# ClinicalTrials.gov record NCT00318461

> PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct00318461-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-03-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00318461-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00318461-liraglutide-v1.json
- Content SHA-256: `5ee5c53aba2113c07951ebe7724cbade20bf70d8c7387cf9013c888d0f9e18e0`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT00318461 ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00318461-2017-03-07-b420376245a1`](#source-ctg-observation-nct00318461-2017-03-07-b420376245a1))

## Sources

<a id="source-ctg-observation-nct00318461-2017-03-07-b420376245a1"></a>
- **ClinicalTrials.gov record NCT00318461 · retained source version 2017-03-07:b420376245a19be08a4635d7fd337be76cd7ec699d0ec5c178d5cba831a84916** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00318461) (`ctg-observation-nct00318461-2017-03-07-b420376245a1`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00318461." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00318461-liraglutide-v1.json SHA-256: 5ee5c53aba2113c07951ebe7724cbade20bf70d8c7387cf9013c888d0f9e18e0.